alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[No. 44207-4-I.

Division One.

March 27, 2000.]

#### Marian Sugano, *Appellant,*v. The University of Washington, *Respondent.*

Appeal from a judgment of the Superior Court for King County, No. 98-2-00128-3, Robert S. Lasnik, J., entered January 28, 1999. *Affirmed in part*and *remanded*by unpublished opinion per Coleman, J., concurred in by Kennedy, C.J., and Appelwick, J.
Electronically Filed Intermediate Court of Appeals CAAP-17-0000321 27-OCT-2017 10:39 AM
News United States Air Force
 Blueprint Leadership with CMSAF Kaleth Wright: Episode 3 featuring SEAC Ramón Colón-LópezPublished Jan. 14, 2020
                        
                        By Anthony Young
                        
                        
                        Secretary of the Air Force Public Affairs
                **ARLINGTON, Va. (AFNS) --**
                Chief Master Sergeant of The Air Force Kaleth O. Wright talks leadership, lessons learned, and shared experiences with the Senior Enlisted Advisor to the Chairman of the Joint Chiefs of Staff, SEAC Ramón Colón-López.CMSAF Kaleth O. Wright 



CMSAF 



SEAC Ramon Colon-Lopez 



Senior Enlisted Advisor to the Chairman of the Joint Chiefs of Staff 



SEAC 



Blueprint Leadership 



Air Force We Need 



talent management 



podcast 



USAF 



AF 



Air Force 



leader 



Teamwork 



mentor 



mentorship 



Senior Leaders
EXHIBIT 23.1

 

 

 

 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

 

 

 

We hereby consent to incorporation by reference of our report dated May 14, 2020, with respect to the consolidated balance sheets of Axim Biotechnologies, Inc. as of December 31, 2019 and 2018, and  the related consolidated statement of operations, statement of shareholders’ deficit and cash flows for the years in the two-year period ended December 31, 2019, which includes an explanatory paragraph regarding the substantial doubt about the Company’s ability to continue as a going concern, included in this Annual Report on Form 10-K of Axim Biotechnologies, Inc. (the “Company”). We hereby consent to the incorporation by reference of said report in the Registration Statements of Axim Biotechnologies, Inc. on Form S-3 (File No. 333-220155).

 

 

 

*//s// RBSM LLP            *

 

New York, New York

May 14, 2020
EXHIBIT 31.2

      CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
           PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

     I, Michael Schumacher, certify that:

     1.   I have reviewed this quarterly report on Form 10-QSB of National
Superstars, Inc.

     2.   Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by
this quarterly report;

     3.   Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

     4.   The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

          a)  designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being
prepared;

          b)  evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the filing date
of this quarterly report (the "Evaluation Date"); and

          c)  presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date.

     5.   The registrant's other certifying officers and I have disclosed,
based on our most recent evaluation, to the registrant's auditors and the
audit committee of registrant's board of directors (or persons performing the
equivalent functions):

          a)  all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have identified for
the registrant's auditors any material weaknesses in internal controls; and

          b)  any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's internal
controls; and

     6.   The registrant's other certifying officers and I have indicated in
this quarterly report whether there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date:  May 18, 2004


 /s/ Michael Schuamcher
Michael Schumacher
Treasurer, Secretary and Chief Financial Officer
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                       <C>
<PERIOD-TYPE>             3-MOS
<FISCAL-YEAR-END>         Oct-31-1999
<PERIOD-START>            Nov-01-1998
<PERIOD-END>              Jan-31-1998
<CASH>                         228768
<SECURITIES>                  1144467
<RECEIVABLES>                  548873
<ALLOWANCES>                        0
<INVENTORY>                     38549
<CURRENT-ASSETS>               874344
<PP&E>                        1590563
<DEPRECIATION>                 636187
<TOTAL-ASSETS>                3360926
<CURRENT-LIABILITIES>          317911
<BONDS>                             0
<COMMON>                        19580
<PREFERRED-MANDATORY>               0
<PREFERRED>                         0
<OTHER-SE>                    2620613 
<TOTAL-LIABILITY-AND-EQUITY>  3360926                   
<SALES>                       1278467
<TOTAL-REVENUES>              1372527 
<CGS>                           53019
<TOTAL-COSTS>                 1239092
<OTHER-EXPENSES>                    0
<LOSS-PROVISION>                    0
<INTEREST-EXPENSE>               1804
<INCOME-PRETAX>                133435
<INCOME-TAX>                        0
<INCOME-CONTINUING>            133435
<DISCONTINUED>                      0
<EXTRAORDINARY>                     0
<CHANGES>                           0
<NET-INCOME>                   133435
<EPS-PRIMARY>                     .03
<EPS-DILUTED>                     .03
        

</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                        National Institute of General Medical Sciences Initial Review Group; Biomedical Research and Research Training Review Subcommittee B.                    

*Date:*                        November 4-5, 2010.                    

*Time:*                        8 a.m. to 5 p.m.                    

*Agenda:*                        To review and evaluate grant applications.                    

*Place:*                        Doubletree Hotel Bethesda (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.                    

*Contact Person:*                        Arthur L. Zachary, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN-18, Bethesda, MD 20892, 301-594-2886,                         *zacharya@nigms.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: September 9, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-23022 Filed 9-14-10; 8:45 am]

BILLING CODE 4140-01-P
ex10-36.htm


Exhibit 10.36








 


AMENDMENT NO. 2 TO SECURITIES PURCHASE AGREEMENT


 







 


This Amendment No. 2 to Securities Purchase Agreement (this “Amendment”), dated as of October 20, 2014, is entered into by and among Medbox, Inc., a Nevada corporation (the “Company”), and the Purchasers named on the signature pages hereto.


 


WITNESSETH:


 


WHEREAS, on July 21, 2014, the Company and the Purchasers entered into a Securities Purchase Agreement, and on  September 19, 2014, the Company and the purchasers entered into an amendment thereto (as amended, the “Securities Purchase Agreement”);


 


WHEREAS, the Company and the Purchasers desire to amend the Securities Purchase Agreement as more particularly set forth below;


 


NOW, THEREFORE, in consideration of the covenants and mutual promises contained herein and other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged and intending to be legally bound hereby, the parties agree as follows:


 


1.           Section 2.4(iv) of the Securities Purchase Agreement shall be deleted in its entirety and replaced by the following which shall be inserted in lieu thereof:


 


There is no existing Event of Default (as defined in the Debentures).


 


2.           Section 2.4(vi) of the Securities Purchase Agreement shall be deleted in its entirety and replaced by the following which shall be inserted in lieu thereof:


 


From the date hereof to the applicable Closing Date, trading in the Common Stock shall not have been suspended by the Commission  or the Company’s principal Trading Market and, at any time prior to the applicable Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities.


 


3.           Except as modified herein, the terms of the Securities Purchase Agreement shall remain in full force and effect.


 


4.           This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and shall be binding upon all parties, their successors and assigns, and all of which taken together shall constitute one and the same Amendment.  A signature delivered by facsimile shall constitute an original.


 


[Signature Page Follows]


 




 





 











 






 


 


[SIGNATURE PAGE TO AMENDMENT TO SECURITIES PURCHASE AGREEMENT]


 


 


IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date set forth above.


 


MEDBOX, INC.


 


By: /s/  Guy Marsala


Name: Guy Marsala


Title: CEO












PURCHASERS:


 


REDWOOD MANAGEMENT LLC


 


By: /s/ John DeNobile


Name: John DeNobile


Title: Manager


 


REDWOOD FUND II LLC


 


By: /s/ John DeNobile


Name: John DeNobile


Title: Manager


 


REDWOOD FUND III LTD.


 


By: /s/ John DeNobile


Name: John DeNobile


Title: Manager
**Exhibit 31.1**

**CERTIFICATION**

I, Patrick White, certify that:

1.     I have reviewed this quarterly report of Form 10-QSB of Document Security Systems, Inc.;

2.     Based on my knowledge, this quarterly report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.     Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;

4.     The registrant’s other certifying officer and I are    responsible for establishing and maintaining disclosure controls and procedures    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control    over financial reporting (as defined in Exchange Act Rules 13a-15(f) and15(d)-15(f), for the registrant and we have: 

a)     Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to me by others within thecompany, particularly during the period in which this quarterly report is being prepared;

b)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this reportbased on such evaluation; 

c)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materiallyaffect, the registrant’s internal control over financial reporting; and 

5.     The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the registrant’s    audit committee of the board of directors (or persons performing the equivalentfunctions); 

 a)     All significant deficiencies and material weaknesses in    the design or operation of internal controls over financial reporting which    are reasonably likely to adversely affect the registrant’s ability to    record, process, summarize and reportfinancial information; and 

b)     Any fraud, whether or not material, that involves management    or other employees who have a significant role in the registrant’s internalcontrols over financial reporting. 

Date: November 14, 2005

/s/Patrick WhitePatrick White

----
[Federal Register Volume 75, Number 178 (Wednesday, September 15, 2010)]
[Notices]
[Page 56135]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-22961]


-----------------------------------------------------------------------

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[WY-923-1310-FI; WYW149955]


Notice of Proposed Reinstatement of Terminated Oil and Gas Lease 
WYW149955, Wyoming

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Mineral Leasing Act of 1920, as 
amended, the Bureau of Land Management (BLM) received a petition for 
reinstatement from Chesapeake Exploration LLC and Khody Land & Minerals 
Company for competitive oil and gas lease WYW149955 for land in 
Converse County, Wyoming. The petition was filed on time and was 
accompanied by all the rentals due since the date the lease terminated 
under the law.

FOR FURTHER INFORMATION CONTACT: Bureau of Land Management, Julie L. 
Weaver, Chief, Fluid Minerals Adjudication, at (307) 775-6176.

SUPPLEMENTARY INFORMATION: The lessees have agreed to the amended lease 
terms for rentals and royalties at rates of $10 per acre or fraction 
thereof, per year and 16\2/3\ percent, respectively. The lessees have 
paid the required $500 administrative fee and $163 to reimburse the 
Department for the cost of this Federal Register notice. The lessees 
have met all the requirements for reinstatement of the lease as set out 
in Sections 31(d) and (e) of the Mineral Lands Leasing Act of 1920 (30 
U.S.C. 188), and the BLM is proposing to reinstate lease WYW149955 
effective April 1, 2010, under the original terms and conditions of the 
lease and the increased rental and royalty rates cited above. The BLM 
has not issued a valid lease to any other interest affecting the lands.

Julie L. Weaver,
Chief, Fluid Minerals Adjudication.
[FR Doc. 2010-22961 Filed 9-14-10; 8:45 am]
BILLING CODE 4310-22-P
[Federal Register Volume 75, Number 177 (Tuesday, September 14, 2010)]
[Notices]
[Page 55743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-22866]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

RIN 0648-XY96


Mid-Atlantic Fishery Management Council; Public Meeting

AGENCY:  National Marine Fisheries Service (NMFS), National Oceanic and 
Atmospheric Administration (NOAA), Commerce.

ACTION:  Notice of public meeting.

-----------------------------------------------------------------------

SUMMARY: The Mid-Atlantic Fishery Management Council's (MAFMC) 
Scientific and Statistical Committee (SSC) will hold a public meeting.

DATES: The meeting will be held on Tuesday, September 21, 2010, from 9 
a.m. to 5 p.m. and Wednesday, September 22, 2010, from 8:30 a.m. to 5 
p.m.

ADDRESSES: The meeting will be held at the Sheraton Four Points, 7032 
Elm Road, Baltimore, MD 21240; telephone: (410) 859-3300.
    Council address: Mid-Atlantic Fishery Management Council, 800 N. 
State Street, Suite 201, Dover, DE 19901; telephone: (302) 674-2331.

FOR FURTHER INFORMATION CONTACT: Christopher M. Moore Ph.D., Executive 
Director, Mid-Atlantic Fishery Management Council, 800 N. State Street, 
Suite 201, Dover, DE 19901; telephone: (302) 526-5255.

SUPPLEMENTARY INFORMATION: Agenda items to be discussed at the SSC 
meeting include: (1) new SSC member orientation; (2) review stock 
assessment information and specify overfishing level and acceptable 
biological catch for spiny dogfish for fishing years 2011-15; review 
and comment on proposed quota specifications and management measures 
for spiny dogfish for fishing years 2011-15; (3) progress report on 
Management Strategy Evaluation study; (4) review and comment on Council 
five year research plan; (5) discuss results of August 12-13, 2010 ACL 
Workshop and planned follow-up joint workshop with NEFSC and New 
England Fishery Management Council's SSC; (6) develop recommendations 
for stock assessment schedule; (7) set 2011 SSC schedule; (8) discuss 
development of Industry Advisory Panel Reports; and (9) discuss 
formation of SSC Ecosystem Subcommittee and development of ecosystem 
terms of reference for the Council.
    To correct an administrative error in providing timely notice of 
this meeting, the Mid-Atlantic Council will conduct a webinar to allow 
public comment on any decisions made at this meeting and allow the SSC 
to ratify those decisions. Notice of the webinar will be published in 
the Federal Register.

Special Accommodations

    The meeting is physically accessible to people with disabilities. 
Requests for sign language interpretation or other auxiliary aids 
should be directed to M. Jan Saunders at the Mid-Atlantic Council 
Office, (302) 526-5251, at least 5 days prior to the meeting date.

    Dated: September 9, 2010.
Tracey L. Thompson,
Acting Director, Office of Sustainable Fisheries, National Marine 
Fisheries Service.
[FR Doc. 2010-22866 Filed 9-13-10; 8:45 am]
BILLING CODE 3510-22-S